Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had its price target lifted by investment analysts at Cantor Fitzgerald from $25.00 to $27.00 in a report issued on Thursday, May 11th. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential downside of 30.14% from the company’s current price.
A number of other analysts have also recently weighed in on the company. Jefferies Group LLC increased their price objective on Supernus Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 8th. Stifel Nicolaus raised their price target on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, April 3rd. Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 28th. Finally, Cowen and Company raised their price target on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, May 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $33.43.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at 38.65 on Thursday. The company has a market cap of $1.94 billion, a PE ratio of 20.79 and a beta of 1.76. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $41.35. The stock’s 50 day moving average is $35.55 and its 200-day moving average is $29.14.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by $0.03. Supernus Pharmaceuticals had a return on equity of 20.76% and a net margin of 17.88%. The company had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million. Equities research analysts expect that Supernus Pharmaceuticals will post $1.08 earnings per share for the current year.
In related news, CFO Gregory S. Patrick sold 54,000 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $32.37, for a total value of $1,747,980.00. Following the completion of the transaction, the chief financial officer now directly owns 54,221 shares of the company’s stock, valued at approximately $1,755,133.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 11,806 shares of the firm’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $32.59, for a total value of $384,757.54. Following the transaction, the vice president now directly owns 45,500 shares of the company’s stock, valued at approximately $1,482,845. The disclosure for this sale can be found here. Insiders sold a total of 83,806 shares of company stock valued at $2,813,038 over the last ninety days. 6.70% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. HighTower Advisors LLC bought a new position in Supernus Pharmaceuticals during the third quarter valued at $464,000. Convergence Investment Partners LLC bought a new position in Supernus Pharmaceuticals during the third quarter valued at $1,496,000. Suntrust Banks Inc. increased its position in Supernus Pharmaceuticals by 1.5% in the third quarter. Suntrust Banks Inc. now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $443,000 after buying an additional 273 shares during the last quarter. State of Tennessee Treasury Department increased its position in Supernus Pharmaceuticals by 47.3% in the third quarter. State of Tennessee Treasury Department now owns 39,380 shares of the specialty pharmaceutical company’s stock valued at $974,000 after buying an additional 12,650 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its position in Supernus Pharmaceuticals by 0.9% in the third quarter. Municipal Employees Retirement System of Michigan now owns 14,550 shares of the specialty pharmaceutical company’s stock valued at $360,000 after buying an additional 130 shares during the last quarter. 92.17% of the stock is owned by institutional investors.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
What are top analysts saying about Supernus Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc and related companies.